The Management of Pain in Spinal Malignancies

  • Susan B. LeGrand
  • Declan Walsh
Part of the Current Clinical Oncology book series (CCO)


The management of pain caused by malignant involvement of the spine can be challenging. The pain is often multifactorial with somatic and neuropathic elements and may be complicated by pre-existing non-malignant pain from arthritis, spinal stenosis, or other chronic back syndromes. The mechanics of the back increase the likelihood of incident pain that may be particularly difficult to control. Excellent pain management requires a team approach that might include palliative medicine, anesthesia pain management, orthotics, and physical medicine and rehabilitation. This chapter focuses on medical management with opioid and adjuvant analgesic agents.


Neuropathic Pain Pain Management Cancer Pain Opioid Medication Incident Pain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pargeon KL, Hailey BJ. Barriers to effective cancer management: a review of the literature. J Pain Symptom Manage 1999; 18:358–368.PubMedCrossRefGoogle Scholar
  2. 2.
    Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain: Adults. Clinical Practice Guideline No. 9 (no.95-0592). Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; 1994.Google Scholar
  3. 3.
    World Health Organization. World Health Organization Technical Support Series. Cancer Pain Relief and Palliative Care (804). Geneva: WHO; 1990.Google Scholar
  4. 4.
    Hill CS Jr. The barriers to adequate pain management with opioid analgesics. Semin Oncol 1993; 20:1–5.PubMedGoogle Scholar
  5. 5.
    Kanner RM, Foley K. Patterns of narcotic drug use in a cancer pain clinic. Ann N Y Acad Sci 1981; 362:161–172.PubMedCrossRefGoogle Scholar
  6. 6.
    Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med 1980; 302:123.PubMedGoogle Scholar
  7. 7.
    Weissman DE, Haddox JD. Opioid pseudoaddiction-an iatrogenic syndrome. Pain 1989; 36:363–366.PubMedCrossRefGoogle Scholar
  8. 8.
    Foley KM. Changing concepts of tolerance to opioids. What the cancer patient has taught us. In: Chapman CR, Foley KM, eds. Current and Emerging Issues in Cancer Pain: Research and Practice. New York, NY: Raven Press; 1993:331–350.Google Scholar
  9. 9.
    Sawe J, Svensson JO, Rane A. Morphine metabolism in cancer patients on increasing oral doses-no evidence for autoinduction or dose dependence. Brit J of Clin Pharmacol 1983; 16:85–93.Google Scholar
  10. 10.
    Haegerstam GA. Pathophysiology of bone pain, a review. Acta Orthop Scand 2001; 72:308–317.PubMedCrossRefGoogle Scholar
  11. 11.
    Ripamonti C, Fulfaro F. Malignant bone pain: pathophysiology and treatments. Current Review of Pain 2000; 4:187–196.PubMedGoogle Scholar
  12. 12.
    Payne R, Gonzalez, GR. Pathophysiology of pain in cancer and other terminal diseases. In: Doyle D, Hanks GW, MacDonald N, eds. Oxford Textbook of Palliative Medicine. Oxford: Oxford Medical Publications; 1998:299–310.Google Scholar
  13. 13.
    World Health Organization. Cancer Pain Relief. Geneva. 1986.Google Scholar
  14. 14.
    Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization guidelines for cancer pain relief. A 10 year prospective study. Pain 1995; 634:65–76.CrossRefGoogle Scholar
  15. 15.
    Allan L, Hays H, Jensen NH, et al. Randomized crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001; 322:1154–1158.CrossRefGoogle Scholar
  16. 16.
    Radbruch L, Sabatowsku R, Loick G, Kulbe C, Kasper M, Grond S. Lehmann KA. Constipation and the use of laxatives: a comparison between transdermal fentayl and oral morphine. Palliat Med 2000; 14:111–119.PubMedCrossRefGoogle Scholar
  17. 17.
    Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47:639–646.PubMedGoogle Scholar
  18. 18.
    Poyhia R, Vainio A, Kalso EJ. A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1983; 8:63–67.CrossRefGoogle Scholar
  19. 19.
    Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1998; 44:335–342.Google Scholar
  20. 20.
    Hoskins PJ, Hanks GW, Aherne GW, et al. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Brit J Clin Pharmacology 1989; 27:499–505.Google Scholar
  21. 21.
    Ripamonti C, Bruera E. Rectal, buccal and sublingual narcotics for management of cancer pain. J Palliat Care 1991; 7:30–35PubMedGoogle Scholar
  22. 22.
    Glare PA, Walsh TD. Clinical pharmacokinetics of morphine. Ther Drug Monit 1990; 13:1–23.Google Scholar
  23. 23.
    Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001; 9:84–96.PubMedCrossRefGoogle Scholar
  24. 24.
    Bruera E, Pereira J, Watanabe S, Hanson J. Opioid rotations in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer 1996; 78:852–857.PubMedCrossRefGoogle Scholar
  25. 25.
    Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997; 72:79–85.PubMedCrossRefGoogle Scholar
  26. 26.
    Miller MG, McCarthy N, O’Boyle CA, Kearney M. Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial. J Pain Symptom Manage 1999; 18:9–16.PubMedCrossRefGoogle Scholar
  27. 27.
    Leow KP, Smith MT, Williams B, et al. Single-dose and steadystate pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992; 52:487–495.PubMedGoogle Scholar
  28. 28.
    Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31:410–422.PubMedCrossRefGoogle Scholar
  29. 29.
    Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 1999; 90:576–579.PubMedCrossRefGoogle Scholar
  30. 30.
    Southarn MA. Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy. Anti-Cancer Drugs, 1995; 6(supplement 3):26–34.Google Scholar
  31. 31.
    Portenoy RK, Payne R Coluzzi P, et al. Oral Transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancers patients: a controlled dose titration study. Pain 1999; 79:303–312.PubMedCrossRefGoogle Scholar
  32. 32.
    Chandler S. Oral transmucosal fentanyl citrate: a new treatment for breakthrough pain. Am J Hosp Palliat Care 1999; 16:489–491.PubMedCrossRefGoogle Scholar
  33. 33.
    Gardner-Nix J. Oral transmucosal fentanyl and sufentanil for incident pain. Journal of pain and symptom management 2001; 22:627–631.PubMedCrossRefGoogle Scholar
  34. 34.
    Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987; 41:392–401.PubMedGoogle Scholar
  35. 35.
    Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001; 9:73–83.PubMedCrossRefGoogle Scholar
  36. 36.
    Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997; 70:109–115.PubMedCrossRefGoogle Scholar
  37. 37.
    Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Gebbia V, Ripamonti C. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19:2898–2904.PubMedGoogle Scholar
  38. 38.
    Morley JS, Makin MK. The use of methadone in cancer pain poorly responsive to other opioids. Pain Reviews 1998; 5:51–58.CrossRefGoogle Scholar
  39. 39.
    Mathew P, Storey P. Subcutaneous methadone in terminally ill patients: manageable local toxicity. J Pain Symptom Manage 1999; 18:49–52.PubMedCrossRefGoogle Scholar
  40. 40.
    Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998; 16:3216–3221.PubMedGoogle Scholar
  41. 41.
    Ripamonti C, De Conno F, Groff L, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 1998; 9:79–83.PubMedCrossRefGoogle Scholar
  42. 42.
    Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematolo Oncol Clin North Am 2002; 16:543–555.CrossRefGoogle Scholar
  43. 43.
    Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs 1994; 47:3–7.PubMedGoogle Scholar
  44. 44.
    Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and non-opioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesia. J Pharmacol Exp Ther 1992; 260:275–285.PubMedGoogle Scholar
  45. 45.
    Wilder-Smith CH, Schimke J, Osterwalder B, Senn HJ. Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 1994; 5:141–146.PubMedGoogle Scholar
  46. 46.
    Grond S, Zech D, Lynch J, Schug S, Lehmann KA. Tramadol-a weak opioid for relief of cancer pain. Pain Clinic 1992; 5:241–247.Google Scholar
  47. 47.
    Jick H, Derby LE, Vasilakis C, Fife D. The risk of seizures associated with tramadol. Pharmacotherapy 1998; 18:607–611.PubMedGoogle Scholar
  48. 48.
    Kahn LH, Alderfer RJ, Graham DJ. Seizures reported with tramadol. JAMA 1997; 278:1661.PubMedCrossRefGoogle Scholar
  49. 49.
    Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996; 59:52–61.PubMedCrossRefGoogle Scholar
  50. 50.
    Savarese JJ, Goldenheim PD, Thomas GB, Kaiko RF. Steady-state pharmacokinetics of controlled release oral morphine sulphate in healthy subjects. Clin Pharmacokinet 1986; 11:505–510.PubMedCrossRefGoogle Scholar
  51. 51.
    Davis M, Wilcock A. Modified release opioids. European Journal of Palliative Care 2001; 8:142–146.Google Scholar
  52. 52.
    Broomhead A, Kerr R, Tester W, et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine for treatment of cancer pain. J Pain Symptom Manage 1997; 14:63–73.PubMedCrossRefGoogle Scholar
  53. 53.
    Portenoy RK, Sciberras A, Eliot L, Loewen G, Butler J, Devaine J. Steady-state pharmacokinetic comparison of a new, extendedrelease, once-daily morphine formulation, Avinza, and a twicedaily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage 2002; 123:292–300.CrossRefGoogle Scholar
  54. 54.
    Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 1996; 46:747–756.CrossRefGoogle Scholar
  55. 55.
    Warfield CA. Controlled-release morphine tablets in patients with chronic cancer pain. Cancer 1998; 82:2299–2306.PubMedCrossRefGoogle Scholar
  56. 56.
    Hanks GW. Controlled release morphine tablets in chronic cancer pain: a review of controlled clinical trials. In: Benedetti C, Chapman CR, Giron G, eds. Advances in Pain Research and Therapy. Vol. 14. New York, NY: Raven Press; 1990:269–274.Google Scholar
  57. 57.
    Sindrup SH, Brosen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5:335–346.PubMedCrossRefGoogle Scholar
  58. 58.
    Hagmeyer KO, Mauro LS, Mauro VE. Meperidine-related seizures associated with patient-controlled analgesia pumps. Ann Pharmacother 1993; 27:29–32.PubMedGoogle Scholar
  59. 59.
    Eisendrath SJ, Goldman B, Douglas J, Dimatteo L, Van Dyke C. Meperidine-induced delirium. Am J Psychiatry 1987; 144:1062–1065.PubMedGoogle Scholar
  60. 60.
    Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13:180–185.PubMedCrossRefGoogle Scholar
  61. 61.
    Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 1991; 41:326–344.PubMedCrossRefGoogle Scholar
  62. 62.
    Portenoy RK. Management of common opioid side effects during long-term therapy of cancer pain. Ann Acad Med 1994; 23:160–170.Google Scholar
  63. 63.
    Hanks G, Cherny N. Opioid analgesic therapy. In: Doyle D, Hanks GWC, MacDonald N, eds. Oxford Textbook of Palliative Medicine. Oxford: Oxford Medical Publications; 1998:331–355.Google Scholar
  64. 64.
    Yee JD, Berde CB. Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J Pain Symptom Manage 1994; 9:122–125.PubMedCrossRefGoogle Scholar
  65. 65.
    Kreeger L, Duncan A, Cowap J. Psychostimulants used for opioidinduced drowsiness. J Pain Symptom Manage 1996; 11:1–2.PubMedCrossRefGoogle Scholar
  66. 66.
    Bruera E, Chadwick S, Brenneis C, Hanson J, MacDonald N. Methylphenidate associated with narcotics in the treatment of cancer pain. Cancer Treat Rep 1987; 71:67–70.PubMedGoogle Scholar
  67. 67.
    Charuluxanan S, Kyokong O, Somboonviboon W, Lertmaharit S, Mgamprasertwong P. Nalbuphine versus propofol for treatment of intrathecal morphine-induced pruritis after cesarean delivery. Anesth Analg 2001; 93:162–165.CrossRefGoogle Scholar
  68. 68.
    Somrat C, Oranuch K, Ketchada U, Siriprapa S, Thipawan R. Optimal dose of nalbuphine for treatment of intrathecal morphineinduced pruritis after caesarian section. J Obstet Gynaecol Res 1999; 25:209–213.PubMedCrossRefGoogle Scholar
  69. 69.
    Bruera E, MacMillan E, Hanson J, et al. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989; 39:13–16.PubMedCrossRefGoogle Scholar
  70. 70.
    Walsh, D. Pharmacological management of cancer pain. Semin Oncol 2000; 27:45–63.PubMedGoogle Scholar
  71. 71.
    Mercandante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain 1998; 74:5–9.CrossRefGoogle Scholar
  72. 72.
    Hagen N, Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration. J Pain Symptom Manage 1997; 14:81–88.Google Scholar
  73. 73.
    Ferris DJ. Controlling myoclonus after high-dosage morphine infusions. Am J Health Syst Pharm 1999; 56:1009–1010.PubMedGoogle Scholar
  74. 74.
    Bruera E, Suarea-Almazor M, Velason A, et al. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: A retrospective review. J Pain Symptom Manage 1994; 9:515–519.PubMedCrossRefGoogle Scholar
  75. 75.
    Schmidt WK. Alvimmopan (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 18:27s–38s.Google Scholar
  76. 76.
    Foss JF. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg 2001; 172:19s–26s.CrossRefGoogle Scholar
  77. 77.
    Borgbjerg FM, Neilsen K, Franks J. Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers. Pain 1996; 64:123–128.PubMedCrossRefGoogle Scholar
  78. 78.
    Moertel GG: Treatment of cancer pain with orally administered medications. JAMA 1980; 244:2448–2450.PubMedCrossRefGoogle Scholar
  79. 79.
    Caraceni A, Gorni G, Zecca E, De Conno F. More on the use of nonsteroidal anti-inflammatories in the management of cancer pain. J Pain Symptom Manage 2001; 21:89–91.PubMedCrossRefGoogle Scholar
  80. 80.
    Jenkins CA, Bruera E. Non-steroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients. Palliat Med 1999; 13:183–196.PubMedCrossRefGoogle Scholar
  81. 81.
    Mannix K, Ahmedzai SH, Anderson H, Bennett M, Lloyd-Williams M, Wilcock A. Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care. Palliat Med 2000; 14:455–461.PubMedCrossRefGoogle Scholar
  82. 82.
    Koeberle D, Bacchus L, Thuerlimann B, Senn HJ. Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. Support Care Cancer 1999; 7:21–27.PubMedCrossRefGoogle Scholar
  83. 83.
    Hutborn R, Gunderson S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double blind placebo controlled multicenter study. Anticancer Res 1999; 19:3383–3392.Google Scholar
  84. 84.
    Vogel CL, Yanagihara RH, Wood AL, et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 2004; 9:687–695.PubMedCrossRefGoogle Scholar
  85. 85.
    Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2005; 3.Google Scholar
  86. 86.
    Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353:99–102.PubMedCrossRefGoogle Scholar
  87. 87.
    Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2001; 4:CD001332.PubMedGoogle Scholar
  88. 88.
    Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database of Syst Rev 2000; 2:CD001131.Google Scholar
  89. 89.
    Loblaw DA, Laperriere NJ. Emergency treatment of malignant spinal cord compression: an evidence-based guideline. J Clin Oncol 1998; 16:1613–1624.PubMedGoogle Scholar
  90. 90.
    Portenoy, RK. Adjuvant analgesics in pain management. In: Doyle D, Hanks GWC, MacDonald, N, eds. Oxford Textbook of Palliative Medicine. Oxford: Oxford Medical Publications; 1998.Google Scholar
  91. 91.
    Sorenson S, Helweg-Larsen S. Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomized trial. Eur J Cancer 1994; 30:22–27.CrossRefGoogle Scholar
  92. 92.
    Vecht CJ, Haaxma-Reiche H, van Putten WL, de Visser M, Vries EP, Twijnstra A. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology 1989; 39:1255–1257.PubMedGoogle Scholar
  93. 93.
    Heimdal K, Hirschberg H, Slettebo H, Watne K, Nome O. High incidence of serious side effects of high-dose dexamethasone treatment in patients with spinal cord compression. J Neurooncol 1992; 12:141–144.PubMedCrossRefGoogle Scholar
  94. 94.
    Lynch ME. Antidepressants as analgesic: a review of randomized controlled trials. J Psychiatry Neurosci 2001; 26:30–36.PubMedGoogle Scholar
  95. 95.
    Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of action. Pain. 83:389–400.Google Scholar
  96. 96.
    Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of the literature. Harv Rev of Psychiatry 2000; 7:257–277.CrossRefGoogle Scholar
  97. 97.
    Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother 2001; 35:557–559.PubMedCrossRefGoogle Scholar
  98. 98.
    Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2000; 3:CD001133.PubMedGoogle Scholar
  99. 99.
    Hindley AC, Hill EB, Leyland MJ, Wiles AE. A double blind controlled trial of salmon calcitonin in pain due to malignancy. Cancer Chemother Pharmacol 1982; 9:71–74.PubMedCrossRefGoogle Scholar
  100. 100.
    Allan E. Calcitonin in the treatment of intractable pain for advanced malignancy. Pharmatherapeutica 1983; 3:482–486.PubMedGoogle Scholar
  101. 101.
    Pecile A. Calcitonin and relief of pain. Bone Miner 1992; 16:187–189.PubMedCrossRefGoogle Scholar
  102. 102.
    Schiraldi GF, Soresi E, Locicero S, Harari S, Scoccia S. Salmon calcitonin in cancer pain: comparison between two different treatment schedules. Int J Clin Pharmacol Ther Toxicol 1987; 25:229–232.PubMedGoogle Scholar
  103. 103.
    Szanto J, Ady N, Jozsef S. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology 1992; 49:180–182.PubMedCrossRefGoogle Scholar
  104. 104.
    Blanchard J, Menk E, Ramamurthy S, Hoffman J. Subarachnoid and epidural calcitonin in patients with pain due to metastatic cancer. J Pain Symptom Manage 1990; 5:42–45.PubMedCrossRefGoogle Scholar
  105. 105.
    Cherny NI, Arbit E, Jain S. Invasive techniques in the management of cancer pain. Hematol Oncol Clin North Am 1996; 10:121–137.PubMedCrossRefGoogle Scholar
  106. 106.
    Hogan Q, Haddox JD, Abram S, Weissman D, Taylor ML, Janjan N. Epidural opiates and local anesthetics for the management of cancer pain. Pain 1991; 46:291–299.CrossRefGoogle Scholar
  107. 107.
    Bedder MD, Burchiel K, Larson A. Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage 1991; 6:368–373.PubMedCrossRefGoogle Scholar
  108. 108.
    Meenan D, Lagares-Garcia JA, Kurek S. Craig D, Green J, Fritz W. Managing intractable pain with an intrathecal catheter and injection port: technique and guidelines. Am Surg 1999; 65:1054–1060.PubMedGoogle Scholar
  109. 109.
    Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids: a critical review and proposals for longterm dosing. J Pain Symptom Manage 2001; 22:672–687.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, Inc., Totowa, NJ 2006

Authors and Affiliations

  • Susan B. LeGrand
    • 1
  • Declan Walsh
    • 2
  1. 1.The Harry R. Horvitz Center for Palliative MedicineThe Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic FoundationCleveland
  2. 2.Palliative Medicine Program, The Harry R. Horvitz Center for Palliative Medicine, The Cleveland Clinic Taussig Cancer CenterThe Cleveland Clinic FoundationCleveland

Personalised recommendations